# Breakthrough Capital

> Breakthrough Capital is a VC fund in Nanjing backing Medical, Health Care and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Nanjing, China
- Total investments: 6
- Last investment: Mar 2022
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.breakthroughcapital.cn

Breakthrough Capital is a venture capital partner that focuses on the transformation and investment of emerging technologies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Biotechnology | 2 | 33% |
| Manufacturing | 2 | 33% |
| Genetics | 1 | 17% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Venture - Series Unknown | 2 | 33% |
| Seed | 1 | 17% |
| Series C | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 5 | 83% |
| Colombia | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sino-Biocan | Zhongbo Ruikang focuses on the research and development of domestic tools in the field of cell and gene therapy, mainly to assist customers in realizing the "continuous, closed, disposable, consistent, scalable, automated, modular, and medical deviceization of cell preparation industrialization. | $15.7M | Series A | Mar 15, 2022 |  |
| REALY | REALY is a medical equipment and device manufacturing company. |  | Venture - Series Unknown | Jan 01, 2022 |  |
| Belle Healthcare | Belle Healthcare provides surgery equipments for hospitals. Their products include lenticule removal forceps, stainless steel belle scissors, capsulotomy scissors, iris scissors, and Vannas capsulotomy scissors. |  | Venture - Series Unknown | Jan 01, 2022 |  |
| Yuce Biological Technology | Shenzhen Yuce Biotechnology Co., Ltd. focuses on genetic testing services for tumor precision immunotherapy, with "gene" + "immunity" as its wings, organically combining tumor genome and immune microenvironment. | $14.1M | Series C | Nov 11, 2021 |  |
| MetWare | Maiwei Metabolism is a developer of novel medical metabolic technology, specializing in the use of cutting-edge metabolomics technology in the domains of life science research and medicine. | $15.5M | Series A | Sep 24, 2021 |  |
| Qinaya | Qinaya offers a range of web design and development, SEO, print advertising, and corporate graphic line services. | $200K | Seed | Feb 23, 2021 |  |

6 of 6 investments shown.

## Co-investors
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 1 deal together
- [Innovation Works](https://shizune.co/investors/profile/innovation-works) — VC Fund, 1 deal together
- [LINK Capital](https://shizune.co/investors/profile/link-capital-edb0) — VC Fund, 1 deal together
- [Rivercity Investment](https://shizune.co/investors/profile/rivercity-investment) — VC Fund, 1 deal together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 1 deal together
- Tzitzit Aseet — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Breakthrough Capital invest in?

Breakthrough Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Breakthrough Capital last invest?

The most recent investment recorded for Breakthrough Capital closed in Mar 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co